IDENTIFY AND TREAT YOUR ALZHEIMER'S SYMPTOMS
The ReCODE Report delivers optimal personalized medical information that allows users and practitioners to achieve unprecedented success in the prevention and reversal of cognitive decline. The report is generated from a very specific set of lab and genome tests curated by Dr. Bredesen. The report includes information of an individual's Alzheimer's subtype, supplemental information of Dr. Bredesen's research, nutitional instruction, hormonal support, and more. The report is desiged to be a starting point and a guide for you and your trained practitioner to start reversing your symptoms.
Alzheimer’s disease is one of the most significant health care problems nationally and globally. Recently, the first description of the reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment), was published. The therapeutic approach used was programmatic and personalized rather than monotherapeutic and invariant, and was dubbed metabolic enhancement for neuro degeneration (MEND). Patients who had to discontinue work were able to return to work, and those struggling at work were able to improve their performance.
ReCODE is currently available in the US for $1,399. The cost includes all necessary assessments, blood labs, genome tests, and access to a Trained Practitioner Locator Tool. For further questions, contact us at support@ahnphealth.com. If you are located outside of the US, you may sign up for our ReVERSE Program.
ReportThe ReCODE engine generates a report for you and your physician. We have created a new category of medical information and analysis where we take highly complex sets of biometric and genetic data sets to generate medical information and a simple image of YOU for you and your physician.
With Dr. Dale Bredesen, Alzheimer’s research pioneer and inventor of the MEND protocol (now superseded by the more sophisticated ReCODE protocol), AHNP Precision Health has created the first software product that identifies subtypes of cognitive decline (types 1-3 Alzheimer’s disease, published by Dr. Bredesen). The report delivers optimal personalized medical information that allows users and practitioners to achieve unprecedented success in the prevention and reversal of cognitive decline. The report is generated from a very specific set of lab and genome tests curated by Dr. Bredesen.
All ReCODE and Bredesen Protocol assessments and initial treatment suggestions must start with a ReCODE Report. AHNP highly recommends consulting with a ReCODE Certified practitioner before starting the protocol. The ReCODE Protocol is a process that may require 3 months to a year of treatment and lifestyle changes to show initial improvement or reversal. Treatment must continue to maintain effective reversal of cognitive decline and continued improvement.
The ReCODE Report costs $1,399, which includes all necessary assessments, blood labs, genome tests, and access to a Trained Practitioner Locator Tool. For further questions, contact us at support@ahnphealth.com.
Report
Keep up to date with Dr. Bredesen's latest research
Reversal of Cognitive Decline in Alzheimer’s Disease
Alzheimer’s disease is one of the most significant healthcare problems nationally and globally. Recently, the
first description of the reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild
cognitive impairment) and SCI (subjective cognitive impairment), was published. The therapeutic approach used was
programmatic and personalized rather than monotherapeutic and invariant, and was dubbed metabolic enhancement for
neurodegeneration (MEND). Patients who had to discontinue work were able to return to work, and those struggling
at work were able to improve their performance. The patients, their spouses, and their co‐workers all reported clear
improvements. READ MORE
Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease
The major genetic risk factor for sporadic Alzheimer's disease (AD) is the lipid binding and transporting carrier protein apolipoprotein E, epsilon 4 allele (ApoE4). One of the unsolved mysteries of AD is how the presence of ApoE4 elicits this age-associated, currently incurable neurodegenerative disease. Recently, we showed that ApoE4 acts as a transcription factor and binds to the promoters of genes involved in a range of processes linked to aging and AD disease pathogenesis. READ MORE
We would love to hear from you. Contact us with any questions or call us at 1.800.450.0805.
Due to increased interest in the ReCODE Report and ReVERSE Program, you may experience a delay in response time.
Terms of Service | Privacy Statement
2018 © Copyright AHNP Precision Health - All rights reserved
